Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056

NCT07909655 is registered in ClinicalTrials.gov with Shanghai Huaota Biopharmaceutical Co., Ltd. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07909655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial Evaluating the Treatment of Idiopathic Pulmonary Fibrosis Patients With HB0056
Lead sponsor
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
December 31, 2028
Enrollment
75 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary fibrosis (ipf)

Arms

As registered; 3 arms.

  • HB0056 group 1 ExperimentalHB0056
  • HB0056 group 2 ExperimentalHB0056
  • control group Placebo comparatorPlacebo

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Change from Baseline in FVC% (Percent of Predicted FVC value) to week 24 24 weeks

Lead sponsor's other trials

Shanghai Huaota Biopharmaceutical Co., Ltd., most recent start first.

Similar trials

Same condition (Idiopathic Pulmonary Fibrosis) and phase, most recent start first.